Business context and reporting period
Filing identity: The supplied filing is Pieris Pharmaceuticals, Inc.’s Form 10-K, not a filing for the company named in the request metadata, Pavella Therapeutics, Inc. It covers the fiscal year ended December 31, 2021, with 2020 comparisons; it does not provide standalone fourth-quarter results. Pieris is a clinical-stage biotechnology company developing Anticalin-based medicines, with programs in respiratory disease and immuno-oncology. Its candidates were not approved for commercial sale, and it had no product-sales revenue.
Financial results and liquidity
| Metric | 2021 | 2020 | Change |
|---|---|---|---|
| Revenue | $31.4 million | $29.3 million | +7.1% |
| Research and development expense | $66.7 million | $46.5 million | +$20.1 million |
| General and administrative expense | $16.6 million | $16.7 million | −$0.1 million |
| Operating loss | $51.8 million | $33.9 million | Loss widened |
| Net loss | $45.7 million | $37.2 million | Loss widened 22.9% |
| Net loss per share, basic and diluted | $0.71 | $0.68 | Loss per share increased |
| Cash used in operating activities | $7.7 million | $45.9 million | Use decreased |
- Revenue consisted of collaboration, license, research-service and milestone amounts. Customer revenue was $27.9 million; collaboration revenue was $3.5 million.
- Research and development spending rose substantially, primarily from immuno-oncology clinical and manufacturing costs, including cinrebafusp alfa and PRS-344/S095012, and increased PRS-220 manufacturing and preclinical work.
- Approximate operating and net margins were negative 165% and negative 146%, respectively, calculated from reported revenue and losses; the filing does not present these margins directly.
- Cash and cash equivalents were $117.8 million at year-end, versus $70.4 million a year earlier. Current assets were $127.6 million and current liabilities $50.6 million, implying working capital of about $77.1 million and a current ratio of about 2.5.
- Operating cash use fell sharply, helped by higher deferred revenue and payables/accruals; it should not be read as a reduction in underlying net losses. Investing activities used $0.9 million; financing activities provided $59.1 million.
- Total liabilities were $102.8 million, including $63.5 million of current and non-current deferred revenue and $13.8 million of long-term operating lease liabilities. No conventional borrowings are shown on the balance sheet.
- Stockholders’ equity was $50.8 million and accumulated deficit was $257.1 million. Common shares outstanding increased from 56.0 million to 72.2 million during 2021.
Material changes and notable items
- 2021 revenue increased $2.1 million year over year. Higher AstraZeneca milestone revenue, new Genentech and Boston Pharmaceuticals agreements, and a Servier milestone were partly offset by lower Seagen and Servier revenue compared with 2020.
- The company recorded $3.7 million of grant income related to PRS-220. Its operating loss widened as R&D expenses grew faster than revenue.
- Financing included $39.7 million of gross proceeds from ATM share sales and $23.0 million of private placements to Seagen and AstraZeneca. The private placements issued 7.3 million common shares in total; ATM sales issued 8.2 million shares.
- The Bavarian government grant supports qualifying PRS-220 development costs for post-COVID pulmonary fibrosis through August 2023, subject to grant conditions and funding thresholds.
Outlook, management commentary and risks
- Management said existing funds were expected to support operations for at least 12 months from the March 1, 2022 filing date, while warning that estimates are uncertain and additional financing may be needed. The company expects continued operating losses and has no product revenue.
- PRS-060/AZD1402’s global Phase 2a asthma study was ongoing under AstraZeneca; Pieris expected topline data in 2022 but said geopolitical conditions could affect study timelines. The filing specifically identifies the Russian invasion of Ukraine as a risk to trial sites and patient follow-up.
- Cinrebafusp alfa entered a two-arm Phase 2 gastric-cancer study in January 2022. The company expected initial data from the HER2-low arm in 2022 and HER2-high arm data in 2023. Phase 1 results cited were interim and from a limited, heavily pretreated patient population.
- PRS-220 was in IND-enabling work, with clinical development planned for 2022 subject to regulatory clearance. PRS-344/S095012 began a Phase 1/2 study in November 2021.
- Key risks include clinical and regulatory failure, reliance on collaborators and contract manufacturers, funding needs and potential shareholder dilution, competition, IP protection, foreign exchange exposure, and COVID-19-related trial or supply disruptions. Pieris reported no material legal proceedings as of the filing date.
- The audit opinion was unqualified. Management assessed disclosure controls and internal control over financial reporting as effective at year-end; the auditor did not express an opinion on internal-control effectiveness. The auditor identified accrued and prepaid clinical-trial expenses as a critical audit matter because of estimation complexity.
Important facts for investors to verify
- Confirm the issuer and filing: this is Pieris Pharmaceuticals, Inc.’s FY2021 10-K, not a Pavella Therapeutics filing or a quarterly report.
- Check subsequent clinical updates, especially PRS-060/AZD1402 timelines and data, the impact of the Ukraine conflict, and Phase 2 results and safety for cinrebafusp alfa.
- Assess cash burn, deferred-revenue timing, grant conditions, and management’s stated runway against later filings; 2021 operating cash use was materially affected by working-capital movements.
- Review further financing and dilution exposure, including ATM capacity, preferred-stock conversion rights, warrants, options and partner resale registrations.
- Confirm collaborator program status, milestone conditions and retained commercial rights; potential milestone totals disclosed are contingent, not committed funding.